CA3089114A1 - Pharmaceutical composition for sustained release delivery of buprenorphine - Google Patents
Pharmaceutical composition for sustained release delivery of buprenorphine Download PDFInfo
- Publication number
- CA3089114A1 CA3089114A1 CA3089114A CA3089114A CA3089114A1 CA 3089114 A1 CA3089114 A1 CA 3089114A1 CA 3089114 A CA3089114 A CA 3089114A CA 3089114 A CA3089114 A CA 3089114A CA 3089114 A1 CA3089114 A1 CA 3089114A1
- Authority
- CA
- Canada
- Prior art keywords
- buprenorphine
- acid
- pharmaceutical composition
- amount
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620317P | 2018-01-22 | 2018-01-22 | |
| US62/620,317 | 2018-01-22 | ||
| PCT/US2019/014422 WO2019144079A1 (en) | 2018-01-22 | 2019-01-21 | Pharmaceutical composition for sustained release delivery of buprenorphine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3089114A1 true CA3089114A1 (en) | 2019-07-25 |
Family
ID=67301573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3089114A Pending CA3089114A1 (en) | 2018-01-22 | 2019-01-21 | Pharmaceutical composition for sustained release delivery of buprenorphine |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11419866B2 (https=) |
| EP (1) | EP3743072B1 (https=) |
| JP (1) | JP2021511326A (https=) |
| CN (1) | CN112236142A (https=) |
| AU (1) | AU2019209416A1 (https=) |
| CA (1) | CA3089114A1 (https=) |
| ES (1) | ES2965836T3 (https=) |
| TW (1) | TW201936191A (https=) |
| WO (1) | WO2019144079A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113117092A (zh) * | 2020-01-14 | 2021-07-16 | 中国科学院上海药物研究所 | 一种非水缓释递药系统 |
| WO2021143745A1 (zh) * | 2020-01-14 | 2021-07-22 | 中国科学院上海药物研究所 | 一种长效罗哌卡因药物组合物及其制备方法和用途 |
| CA3211413A1 (en) * | 2021-02-18 | 2022-08-25 | Navin Saxena Research And Technology Private Limited | Non-aqueous injectable composition for sustained release of buprenorphine and use thereof |
| KR20250036827A (ko) * | 2022-06-24 | 2025-03-14 | 에일러 파마슈티컬스 아이엔씨. | 부프레노르핀의 안정한 약제학적 조성물 및 이의 제조 방법 및 용도 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8533582A (en) * | 1981-07-10 | 1984-01-12 | Reckitt & Colman Products Limited | Stable solutions of buprenorphine |
| US4626539A (en) | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| CA2002299A1 (en) * | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
| IT1302682B1 (it) | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | Composizioni farmaceutiche orali contenenti buprenorfina |
| EP1554290B1 (en) | 2002-10-25 | 2009-09-30 | Euro-Celtique S.A. | Analogs and prodrugs of buprenorphine |
| CN1263760C (zh) | 2002-11-12 | 2006-07-12 | 财团法人奇美医院 | 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物 |
| US8236292B2 (en) | 2004-06-04 | 2012-08-07 | Camurus Ab | Liquid depot formulations |
| AU2006316607A1 (en) * | 2005-11-21 | 2007-05-31 | Schering-Plough Pty. Limited | Pharmaceutical compositions comprising buprenorphine |
| US20090270438A1 (en) * | 2006-10-18 | 2009-10-29 | Clive Booles | Novel compositions and formulations |
| EP2262367A4 (en) * | 2008-03-08 | 2011-04-20 | Theraquest Biosciences Inc | PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE |
| CN102113008A (zh) | 2008-05-30 | 2011-06-29 | 兰迪帕特网络公司 | 用于提供在线服务和软件的方法和系统 |
| GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| AU2011295694B2 (en) * | 2010-09-03 | 2015-02-05 | Zoetis Belgium S.A. | High dose buprenorphine compositions and use as analgesic |
| WO2014016428A1 (en) | 2012-07-26 | 2014-01-30 | Camurus Ab | Opioid formulations |
| US9918981B2 (en) * | 2013-09-10 | 2018-03-20 | Insys Development Company, Inc. | Liquid buprenorphine formulations |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| CA3015557C (en) | 2014-11-07 | 2019-07-16 | Indivior Uk Limited | The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders |
-
2019
- 2019-01-21 WO PCT/US2019/014422 patent/WO2019144079A1/en not_active Ceased
- 2019-01-21 EP EP19741052.5A patent/EP3743072B1/en active Active
- 2019-01-21 AU AU2019209416A patent/AU2019209416A1/en not_active Abandoned
- 2019-01-21 JP JP2020539792A patent/JP2021511326A/ja active Pending
- 2019-01-21 US US16/962,040 patent/US11419866B2/en active Active
- 2019-01-21 ES ES19741052T patent/ES2965836T3/es active Active
- 2019-01-21 CA CA3089114A patent/CA3089114A1/en active Pending
- 2019-01-21 CN CN201980009501.7A patent/CN112236142A/zh active Pending
- 2019-01-22 TW TW108102619A patent/TW201936191A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3743072A1 (en) | 2020-12-02 |
| CN112236142A (zh) | 2021-01-15 |
| WO2019144079A1 (en) | 2019-07-25 |
| ES2965836T3 (es) | 2024-04-17 |
| EP3743072B1 (en) | 2023-10-25 |
| US11419866B2 (en) | 2022-08-23 |
| JP2021511326A (ja) | 2021-05-06 |
| EP3743072C0 (en) | 2023-10-25 |
| US20200345724A1 (en) | 2020-11-05 |
| EP3743072A4 (en) | 2021-09-22 |
| TW201936191A (zh) | 2019-09-16 |
| AU2019209416A1 (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3743072B1 (en) | Pharmaceutical composition for sustained release delivery of buprenorphine | |
| US10517864B2 (en) | Sustained-release buprenorphine solutions | |
| KR101892496B1 (ko) | 팔리페리돈 임플란트 제형 | |
| EP2529756B1 (en) | Risperidone and/or Paliperidone implant formulation | |
| KR102541281B1 (ko) | 주사가능한 부프레노르핀 제형 | |
| KR20150041794A (ko) | 오피오이드 제형 | |
| CN109010255B (zh) | 阿片样物质制剂 | |
| MX2014000454A (es) | Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas. | |
| KR101238703B1 (ko) | 경구 투여용 담체 | |
| KR20180085716A (ko) | 방출 조절 제제 | |
| KR101892797B1 (ko) | 향상된 안정성을 갖는 척수강내 히드로모르폰 용액 | |
| US20240139145A1 (en) | Non-aqueous injectable composition or sustained release of buprenorphine and use thereof | |
| EP3441073A1 (en) | Medicinal composition | |
| KR101785319B1 (ko) | 안정성이 향상된 콜레칼시페롤 조성물 및 이의 제조방법 |